Conatus benefits from Hep C drug excitement

Although traders are taking profits today, nano cap Conatus Pharmaceuticals (CNAT -17.3%) looks like it may ride the rising tide of investor enthusiasm for hepatitis drugs led by the wildly successful launch of Gilead's (GILD +0.2%) Hep C treatment Sovaldi. Yesterday, shares popped 57% on a 19-fold surge in volume.

The company's lead product is emricasan, a orally-active caspase protease inhibitor designed to reduce the activity of enzymes the mediate inflammation and apoptosis (cell death). The company believes it has the potential to interrupt the progression of liver disease. Four Phase 2 clinical trials are underway to assess its safety and efficacy in acute-on-chronic liver failure, chronic liver failure, post-liver transplant HCV clearance with unresolved fibrosis and nonalcoholic steatohepatitis.

The company debuted almost a year ago on July 25, 2013 at $11. Prices quickly retreated closing at $9.50 on Day 1. It bottomed at $5.06 on May 14.

From other sites
Comments (1)
  • chicagomary
    , contributor
    Comments (465) | Send Message
    I wonder if the jump in $CNAT yesterday is why $EPZM was up yesterday and today???
    12 Jun 2014, 02:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs